Please select an option below to help us tailor your newsletter to best suit your content interests!
Colorectal, colon, rectum, rectal
Stage 4
Phase 2
Open to Enrollment
1st Line
Onvansertib
Polo-like kinase 1 inhibitor
Brad Somer, MD
Cardiff Oncology
Adenocarcinoma
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
VIEW TRIAL ON CLINICALTRIALS.GOVColon cancer, rectal cancer, colorectal cancer
Stage 4
Phase 2
Open to Enrollment
1st Line
encorafenib, cetuximab, pembrolizumab
BRAF inhibitor, EGFR mAb, PD-1 inhibitor
Brad Somer, MD
Pfizer
BRAF V600 mutant, MSI-h, dMMR
AndroMETa-CRC-064 Abbvie M24-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVColorectal, colon, rectum, rectal
Stage 4
Phase 3
Open to Enrollment
3rd or later
ABBV-400
Anti-cMET ADC
Axel Grothey, MD
Abbvie
Adenocarcinoma